Search

everythinglearnresearchcommunity

for

Search:↓

Considering treatments for hair loss, including Minoxidil, Finasteride, RU58841, Fluridil and Pyrilutamide. The user is weighing the risks of taking unapproved medication before it has been mass produced.

Dutasteride at 0.5 mg/day does not significantly alter allopregnanolone levels, but higher doses (2.5 mg/day) do. Dutasteride may also have anti-neuroinflammatory effects, but the impact on neurosteroids is still debated.

The user has been using finasteride for hair loss and is considering adding RU58841. They ask about RU58841's effectiveness, potential heart side effects, duration of action, dosage increase over time, transitioning to GT20029, and where to find the liquid form.

A 25-year-old woman with androgenic alopecia has been using minoxidil, spironolactone, and dutasteride but sees little improvement in hair thinning. She is considering switching to oral minoxidil and exploring other treatments like PRP and hair systems.

Stemoxydine is not a DHT blocker; it works independently to stimulate hair growth. Users discussed its function and clarified it does not block DHT.

RU58841 had mixed results for hair regrowth, with some users experiencing no change and others noting regrowth but also side effects like libido issues and chest pain. Some users combined it with other treatments like finasteride and dutasteride, with varying effectiveness.

Rhamnose may promote hair growth and pigmentation, suggesting it as a potential hair loss treatment. The conversation discusses its potential alongside known treatments like Minoxidil, finasteride, and RU58841.

Dutasteride effectively stops hair loss but can cause side effects like sexual dysfunction, muscle mass changes, and testicle shrinkage. Adjusting the dosage may help manage these side effects, but long-term health effects remain a concern.

The conversation discusses using RU58841 with octopirox or essential oils for hair loss treatment. The user is seeking advice on which variation to try.

Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgen receptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.